🎯 German biotech Adrenomed has received fast track designation from the FDA for its septic shock therapy enibarcimab.
🩸 The treatment restores the integrity of the endothelium, leading to a reduction in mortality rates.
🚀 Adrenomed plans to begin a pivotal Phase IIb study to further validate the therapy’s effectiveness.
💊 Enibarcimab acts like a hoover for the vasoactive peptide adrenomedullin, fixing it to the intravascular compartment and restoring endothelial function.
💡The therapy has the potential to become the first effective and targeted treatment for septic shock.
🩸 The treatment restores the integrity of the endothelium, leading to a reduction in mortality rates.
🚀 Adrenomed plans to begin a pivotal Phase IIb study to further validate the therapy’s effectiveness.
💊 Enibarcimab acts like a hoover for the vasoactive peptide adrenomedullin, fixing it to the intravascular compartment and restoring endothelial function.
💡The therapy has the potential to become the first effective and targeted treatment for septic shock.
📢 Game-Changing FDA Fast Track for Breakthrough Septic Shock Treatment!
Introduction:
German company AdrenoMed AG has been granted FDA Fast Track designation for its septic shock treatment, enibarcimab, which restores endothel integrity. The company plans to start a pivotal Phase IIb study to further develop the treatment.
Main points:
- AdrenoMed AG’s septic shock treatment, enibarcimab, has received FDA Fast Track designation.
- Enibarcimab acts as a “hoover” for the adrenomedullin peptide, fixing it to the intravascular compartment to restore the barrier function of the endothelium.
- Preclinical studies have shown that enibarcimab alleviates the symptoms of septic shock by shifting the adrenomedullin balance to the intravascular space.
- In clinical studies, the response to enibarcimab was highest in patients with elevated levels of two blood biomarkers: adrenomedullin and DPP3.
- If approved, enibarcimab would be the first effective and targeted treatment for septic shock, with significant market potential.
Conclusion:
AdrenoMed AG’s septic shock treatment, enibarcimab, has received FDA Fast Track designation. The treatment has shown promising results in preclinical and clinical studies, and if approved, could be the first effective and targeted treatment for septic shock. This designation is a validation of AdrenoMed’s commitment to precision medicine in the intensive care unit, and could greatly improve patient outcomes in the future.
